ACTL8

Summary

ACTL8 (actin like 8, HGNC:24018) is a protein-coding gene on chromosome 1p36.13, encoding Actin-like protein 8 (Q9H568).

Predicted to enable protein kinase binding activity. Predicted to be a structural constituent of postsynaptic actin cytoskeleton. Involved in epithelial cell differentiation. Predicted to be located in cytoskeleton. Predicted to be part of NuA4 histone acetyltransferase complex. Predicted to be active in several cellular components, including actin filament; axon; and synapse.

Source: NCBI Gene 81569 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 65 total — 5 pathogenic
• Phenotypes (HPO): 1
• Druggable target: yes
• MANE Select transcript: NM_030812

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24018
Approved symbol	ACTL8
Name	actin like 8
Location	1p36.13
Locus type	gene with protein product
Status	Approved
Aliases	CT57
Ensembl gene	ENSG00000117148
Ensembl biotype	protein_coding
OMIM	621132
Entrez	81569

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 protein_coding

ENST00000375406, ENST00000617065, ENST00000922969, ENST00000922970, ENST00000967949, ENST00000967950

RefSeq mRNA: 1 — MANE Select: NM_030812 NM_030812

CCDS: CCDS183

Canonical transcript exons

ENST00000375406 — 3 exons

Exon	Start	End
ENSE00001267551	17822985	17823356
ENSE00001466977	17825767	17827063
ENSE00001466981	17755333	17755504

Expression profiles

Bgee: expression breadth broad, 28 present calls, max score 99.97.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.9544 / max 202.2875, expressed in 160 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
1015	0.9544	160

Top tissues by expression

275 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	99.97	gold quality
secondary oocyte	CL:0000655	99.92	gold quality
olfactory bulb	UBERON:0002264	91.15	gold quality
type B pancreatic cell	CL:0000169	89.55	gold quality
diaphragm	UBERON:0001103	83.72	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.17	gold quality
male germ cell	CL:0000015	80.56	gold quality
upper arm skin	UBERON:0004263	80.37	gold quality
sperm	CL:0000019	79.36	gold quality
cervix squamous epithelium	UBERON:0006922	79.31	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	79.23	gold quality
orbitofrontal cortex	UBERON:0004167	76.65	gold quality
tongue squamous epithelium	UBERON:0006919	76.36	gold quality
thymus	UBERON:0002370	75.23	gold quality
cervix epithelium	UBERON:0004801	74.45	gold quality
lateral nuclear group of thalamus	UBERON:0002736	73.72	gold quality
dorsal plus ventral thalamus	UBERON:0001897	73.67	gold quality
pons	UBERON:0000988	73.62	gold quality
subthalamic nucleus	UBERON:0001906	73.56	gold quality
vena cava	UBERON:0004087	73.54	gold quality
ventral tegmental area	UBERON:0002691	73.00	gold quality
gluteal muscle	UBERON:0002000	72.93	gold quality
inferior vagus X ganglion	UBERON:0005363	72.85	gold quality
epithelial cell of pancreas	CL:0000083	72.48	gold quality
triceps brachii	UBERON:0001509	72.14	gold quality
right testis	UBERON:0004534	71.85	gold quality
cardia of stomach	UBERON:0001162	71.77	gold quality
substantia nigra pars compacta	UBERON:0001965	71.74	gold quality
body of tongue	UBERON:0011876	71.68	gold quality
tongue	UBERON:0001723	71.58	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.81

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

14 targeting ACTL8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-548AS-3P	99.12	69.12	2294
HSA-MIR-2115-5P	98.66	68.07	1191
HSA-MIR-548AT-3P	98.37	64.98	580
HSA-MIR-548AY-3P	98.37	65.14	562
HSA-MIR-4717-5P	98.19	67.97	894
HSA-MIR-6801-3P	98.04	64.64	805
HSA-MIR-6810-3P	97.96	64.57	1023
HSA-MIR-3664-3P	97.85	67.62	1452
HSA-MIR-4308	97.56	67.13	1385

Literature-anchored findings (GeneRIF, showing 3)

• Actin-like protein 8 promotes cell proliferation, colony-formation, proangiogenesis, migration and invasion in lung adenocarcinoma cells. (PMID:31962007)
• Actin-like protein 8, a member of cancer/testis antigens, supports the aggressive development of oral squamous cell carcinoma cells via activating cell cycle signaling. (PMID:35051678)
• ACTL8 Promotes the Progression of Gastric Cancer Through PI3K/AKT/mTOR Signaling Pathway. (PMID:39322809)

Cross-species orthologs

0 orthologs

Paralogs (26): ACTR6 (ENSG00000075089), ACTB (ENSG00000075624), ACTL6B (ENSG00000077080), ACTR5 (ENSG00000101442), ACTR3C (ENSG00000106526), ACTA2 (ENSG00000107796), ACTR8 (ENSG00000113812), ACTR1B (ENSG00000115073), ACTR3 (ENSG00000115091), ACTRT1 (ENSG00000123165), ACTR10 (ENSG00000131966), ACTR3B (ENSG00000133627), ACTL6A (ENSG00000136518), ACTR2 (ENSG00000138071), ACTR1A (ENSG00000138107), ACTA1 (ENSG00000143632), ACTL7B (ENSG00000148156), ACTC1 (ENSG00000159251), ACTG2 (ENSG00000163017), ACTBL2 (ENSG00000169067), ACTRT2 (ENSG00000169717), ACTL9 (ENSG00000181786), ACTG1 (ENSG00000184009), ACTRT3 (ENSG00000184378), ACTL7A (ENSG00000187003), ACTL10 (ENSG00000288649)

Protein

Protein identifiers

Actin-like protein 8 — Q9H568 (reviewed: Q9H568)

Alternative names: Cancer/testis antigen 57

All UniProt accessions (1): Q9H568

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Cytoplasm. Cytoskeleton.

Tissue specificity. Strongly expressed in testis and pancreas. Weak expression in placenta.

Similarity. Belongs to the actin family.

RefSeq proteins (1): NP_110439* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004000	Actin	Family
IPR043129	ATPase_NBD	Homologous_superfamily

Pfam: PF00022

UniProt features (3 total): sequence variant 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H568-F1	88.51	0.66

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 63 (showing top): GOBP_EPITHELIUM_DEVELOPMENT, GOBP_NEUROGENESIS, GOBP_CELL_JUNCTION_ORGANIZATION, GOCC_NEURON_PROJECTION, GOBP_CELL_PROJECTION_ORGANIZATION, GRADE_COLON_AND_RECTAL_CANCER_DN, SHEN_SMARCA2_TARGETS_DN, GOCC_H4_HISTONE_ACETYLTRANSFERASE_COMPLEX, VECCHI_GASTRIC_CANCER_ADVANCED_VS_EARLY_UP, GOCC_TRANSFERASE_COMPLEX, GOCC_SYNAPSE, GOCC_AXON, GOMF_KINASE_BINDING, GOMF_STRUCTURAL_CONSTITUENT_OF_CYTOSKELETON, GOMF_STRUCTURAL_MOLECULE_ACTIVITY

GO Biological Process (4): axonogenesis (GO:0007409), epithelial cell differentiation (GO:0030855), cell motility (GO:0048870), postsynaptic actin cytoskeleton organization (GO:0098974)

GO Molecular Function (3): protein kinase binding (GO:0019901), structural constituent of postsynaptic actin cytoskeleton (GO:0098973), protein binding (GO:0005515)

GO Cellular Component (8): cytoplasm (GO:0005737), actin filament (GO:0005884), actin cytoskeleton (GO:0015629), membrane (GO:0016020), axon (GO:0030424), NuA4 histone acetyltransferase complex (GO:0035267), synapse (GO:0045202), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
cell morphogenesis involved in neuron differentiation	1
neuron projection morphogenesis	1
axon development	1
cell differentiation	1
epithelium development	1
cellular process	1
actin cytoskeleton organization	1
postsynaptic cytoskeleton organization	1
kinase binding	1
structural constituent of cytoskeleton	1
postsynaptic actin cytoskeleton	1
postsynaptic actin cytoskeleton organization	1
structural constituent of postsynapse	1
binding	1
intracellular anatomical structure	1
actin cytoskeleton	1
polymeric cytoskeletal fiber	1
cytoskeleton	1
neuron projection	1
H4/H2A histone acetyltransferase complex	1
cell junction	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

2112 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ACTL8	XAGE3	Q8WTP9	667
ACTL8	CT83	Q5H943	542
ACTL8	AQP7B	A0A075B734	517
ACTL8	CT55	Q8WUE5	507
ACTL8	CT45A1	Q5HYN5	507
ACTL8	PASD1	Q8IV76	505
ACTL8	GAGE2A	Q6NT46	457
ACTL8	XAGE1B	Q9HD64	447
ACTL8	OIP5	O43482	445
ACTL8	A0A1W2PQG5	A0A1W2PQG5	432
ACTL8	C4orf51	C9J302	432
ACTL8	CSAG2	Q9Y5P2	418
ACTL8	CTCFL	Q8NI51	408
ACTL8	EPPIN	O95925	399
ACTL8	MAGEB6	Q8N7X4	396

IntAct

29 interactions, top by confidence:

A	B	Type	Score
CERT1	ACTL8	psi-mi:“MI:0915”(physical association)	0.560
ACTL8	CERT1	psi-mi:“MI:0915”(physical association)	0.560
Snw1	AKR7A2	psi-mi:“MI:0914”(association)	0.350
Ranbp2	POM121C	psi-mi:“MI:0914”(association)	0.350
RACGAP1	STX18	psi-mi:“MI:0914”(association)	0.350
RNF2	AKIP1	psi-mi:“MI:0914”(association)	0.350
Cct4	ARHGAP32	psi-mi:“MI:0914”(association)	0.350
TCEAL4	USP11	psi-mi:“MI:0914”(association)	0.350
Cct2	OSBPL9	psi-mi:“MI:0914”(association)	0.350
Skp1	XPO1	psi-mi:“MI:0914”(association)	0.350
Cct3	PFDN1	psi-mi:“MI:0914”(association)	0.350
Cct8	DTL	psi-mi:“MI:0914”(association)	0.350
Pcgf1	SCAMP3	psi-mi:“MI:0914”(association)	0.350
BCOR	HSPD1	psi-mi:“MI:0914”(association)	0.350
TCF20	MTA3	psi-mi:“MI:0914”(association)	0.350
Kif19	NBAS	psi-mi:“MI:0914”(association)	0.350
MYO5C	CLIC1	psi-mi:“MI:0914”(association)	0.350
TWNK	RAD9A	psi-mi:“MI:0914”(association)	0.350
MYC	TARS3	psi-mi:“MI:0914”(association)	0.350
Uso1	SLC30A6	psi-mi:“MI:0914”(association)	0.350
TRIM29	SEC16A	psi-mi:“MI:0914”(association)	0.350
VPS26B	KIF1B	psi-mi:“MI:0914”(association)	0.350
USP7	STIL	psi-mi:“MI:0914”(association)	0.350
PLEKHA7	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
ACTL8	CERT1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (30): ACTL8 (Two-hybrid), ACTL8 (Affinity Capture-MS), ACTL8 (Affinity Capture-MS), ACTL8 (Affinity Capture-MS), ACTL8 (Affinity Capture-MS), ACTL8 (Affinity Capture-MS), ACTL8 (Affinity Capture-MS), ACTL8 (Affinity Capture-MS), ACTL8 (Affinity Capture-MS), ACTL8 (Affinity Capture-MS), ACTL8 (Affinity Capture-MS), ACTL8 (Affinity Capture-MS), ACTL8 (Affinity Capture-MS), ACTL8 (Affinity Capture-MS), ACTL8 (Affinity Capture-MS)

ESM2 similar proteins: A2YUL5, A4IFE3, A7MB62, O94241, O94630, O96621, P02583, P20360, P32381, P38673, P38696, P42023, P42025, P45888, P45889, P53487, P53488, P53489, P53503, P61160, P61161, P61162, P61163, P61164, P85515, Q2TA43, Q4R6J9, Q4R821, Q54HE7, Q54HE9, Q54I79, Q56A35, Q5BL41, Q5M7U6, Q5R4K0, Q5XIK1, Q61JZ2, Q641W9, Q6Z256, Q7SXW6

Diamond homologs: A2AKE7, P10994, P24902, P26183, P30161, P45521, P45891, P53477, P53499, P53502, P80428, P84856, Q09849, Q25379, Q25380, Q25381, Q4IPI4, Q4WHA3, Q55CU2, Q5AC48, Q5AW89, Q5JWF8, Q6BXN0, Q6C061, Q6CSB9, Q6FJV8, Q754G5, Q96484, Q9H568, Q9P7X7, A2YR10, D0LWX4, P38696, Q24733, Q2T9W4, Q32KZ2, Q4R317, Q4R6Q3, Q4R821, Q641W9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

65 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	5
Likely pathogenic	0
Uncertain significance	54
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
1340990	GRCh37/hg19 1p36.13(chr1:16773001-20221073)x1	Pathogenic
3062822	GRCh37/hg19 1p36.21-36.12(chr1:16194137-20561434)x1	Pathogenic
4846749	GRCh38/hg38 1p36.13(chr1:16950757-19234873)x1	Pathogenic
57443	GRCh38/hg38 1p36.21-36.12(chr1:15385267-20980349)x1	Pathogenic
58056	GRCh38/hg38 1p36.21-36.13(chr1:13619979-18466172)x3	Pathogenic

SpliceAI

881 predictions. Top by Δscore:

Variant	Effect	Δscore
1:17822981:GCAG:G	acceptor_loss	1.0000
1:17822983:A:AG	acceptor_gain	1.0000
1:17822983:AG:A	acceptor_gain	1.0000
1:17822984:G:GG	acceptor_gain	1.0000
1:17822984:G:GT	acceptor_loss	1.0000
1:17822984:GG:G	acceptor_gain	1.0000
1:17822984:GGTCC:G	acceptor_gain	1.0000
1:17823354:G:GT	donor_gain	1.0000
1:17823355:AGG:A	donor_loss	1.0000
1:17823356:GGTGA:G	donor_loss	1.0000
1:17823358:T:A	donor_loss	1.0000
1:17825761:TTGCA:T	acceptor_loss	1.0000
1:17825762:TGCA:T	acceptor_loss	1.0000
1:17825763:GCA:G	acceptor_loss	1.0000
1:17825764:CA:C	acceptor_loss	1.0000
1:17825765:A:AG	acceptor_gain	1.0000
1:17825765:AGA:A	acceptor_loss	1.0000
1:17825766:G:GA	acceptor_loss	1.0000
1:17825766:G:GG	acceptor_gain	1.0000
1:17822984:GGT:G	acceptor_gain	0.9900
1:17822984:GGTC:G	acceptor_gain	0.9900
1:17825759:C:CA	acceptor_gain	0.9900
1:17825766:GATC:G	acceptor_gain	0.9900
1:17755502:CTGG:C	donor_loss	0.9800
1:17755506:TAC:T	donor_loss	0.9800
1:17822980:C:CA	acceptor_gain	0.9800
1:17823353:GGAG:G	donor_gain	0.9800
1:17823354:GAG:G	donor_gain	0.9800
1:17823357:G:GG	donor_gain	0.9800
1:17825766:GATCC:G	acceptor_gain	0.9800

AlphaMissense

2396 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:17823056:G:C	K16N	0.992
1:17823056:G:T	K16N	0.992
1:17823252:T:A	W82R	0.992
1:17823252:T:C	W82R	0.992
1:17826430:T:A	W338R	0.992
1:17826430:T:C	W338R	0.992
1:17825852:G:A	G145E	0.989
1:17826437:G:A	G340E	0.989
1:17826314:G:A	G299E	0.987
1:17826321:C:A	N301K	0.987
1:17826321:C:G	N301K	0.987
1:17826314:G:T	G299V	0.986
1:17826196:T:C	F260L	0.985
1:17826198:T:A	F260L	0.985
1:17826198:T:G	F260L	0.985
1:17826436:G:A	G340R	0.985
1:17826436:G:C	G340R	0.985
1:17823233:G:C	W75C	0.983
1:17823233:G:T	W75C	0.983
1:17826437:G:T	G340V	0.983
1:17823082:C:A	P25H	0.981
1:17825798:T:A	V127D	0.981
1:17825861:T:A	V148D	0.981
1:17825896:T:C	F160L	0.981
1:17825898:C:A	F160L	0.981
1:17825898:C:G	F160L	0.981
1:17826197:T:C	F260S	0.981
1:17826347:G:C	R310P	0.981
1:17825866:T:C	S150P	0.980
1:17825969:T:C	L184P	0.980

dbSNP variants (sampled 300 via entrez): RS1000000510 (1:17754892 T>C,G), RS1000013390 (1:17820438 A>G), RS1000046339 (1:17781674 G>T), RS1000069946 (1:17796640 G>A), RS1000207830 (1:17824857 A>C), RS1000211980 (1:17798570 T>A), RS1000218151 (1:17803946 C>T), RS1000221512 (1:17791577 G>A,T), RS1000229467 (1:17766142 C>T), RS1000313484 (1:17760599 A>G), RS1000349080 (1:17780344 G>C), RS1000415719 (1:17821361 C>T), RS1000478506 (1:17792603 G>A), RS1000487981 (1:17754878 C>A,G), RS1000490805 (1:17820131 G>A)

Disease associations

OMIM: gene MIM:621132 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): breast ductal adenocarcinoma (MONDO:0005590), hypertrophic cardiomyopathy (MONDO:0005045)

Orphanet (1): Rare hypertrophic cardiomyopathy (Orphanet:217569)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0001639	Hypertrophic cardiomyopathy

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST001762_503	Obesity-related traits	3.000000e-06
GCST006993_1	Hippocampal volume in Alzheimer’s disease dementia	3.000000e-07
GCST008173_1	Alanine aminotransferase levels	4.000000e-06
GCST008359_3	Response to cognitive-behavioural therapy in anxiety disorder	1.000000e-06
GCST009391_1266	Metabolite levels	4.000000e-06
GCST009391_1397	Metabolite levels	2.000000e-06

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004730	hormone measurement
EFO:0005035	hippocampal volume
EFO:0007820	cognitive behavioural therapy
EFO:0010545	uridine diphosphate measurement
EFO:0010369	lysophosphatidylethanolamine 18:2 measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390
D002312	Cardiomyopathy, Hypertrophic	C14.280.238.100; C14.280.484.048.750.070.160

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724738 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases methylation, increases expression	2
Esketamine	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
rutecarpine	decreases expression	1
CGP 52608	affects binding, increases reaction	1
(+)-JQ1 compound	decreases expression	1
Acetaminophen	decreases expression	1
Estradiol	increases expression	1
Fluorouracil	affects reaction, decreases expression	1
Niclosamide	decreases expression	1
Silicon Dioxide	increases expression	1
Triclosan	increases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	increases expression	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5697459	Binding	Inhibition of ACTL8 (unknown origin) assessed as fold change at 10 uM incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7JG	Ubigene A-549 ACTL8 KO	Cancer cell line	Male

Clinical trials (associated diseases)

238 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00879060	PHASE4	COMPLETED	Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
NCT01721967	PHASE4	COMPLETED	Ranolazine for the Treatment of Chest Pain in HCM Patients
NCT02948998	PHASE4	UNKNOWN	Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy
NCT03249272	PHASE4	TERMINATED	Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
NCT04133532	PHASE4	COMPLETED	Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy
NCT06401343	PHASE4	RECRUITING	Use of SGLT2i in noHCM With HFpEF
NCT07103655	PHASE4	NOT_YET_RECRUITING	The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
NCT07600177	PHASE4	RECRUITING	Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00317967	PHASE3	COMPLETED	Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart
NCT00698074	PHASE3	UNKNOWN	Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy
NCT00821353	PHASE3	COMPLETED	Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy
NCT02431221	PHASE3	WITHDRAWN	Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure
NCT03470545	PHASE3	COMPLETED	Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT05174416	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
NCT05182658	PHASE3	ACTIVE_NOT_RECRUITING	Empagliflozin in Hypertrophic Cardiomyopathy
NCT05186818	PHASE3	COMPLETED	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
NCT05767346	PHASE3	COMPLETED	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT06116968	PHASE3	COMPLETED	An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
NCT06873828	PHASE3	NOT_YET_RECRUITING	Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
NCT07021976	PHASE3	RECRUITING	A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT07023341	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT07202897	PHASE3	NOT_YET_RECRUITING	LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00001631	PHASE2	COMPLETED	Study of Blood Flow in Heart Muscle
NCT00001894	PHASE2	COMPLETED	A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy
NCT00001960	PHASE2	COMPLETED	Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle
NCT00011076	PHASE2	COMPLETED	Pirfenidone to Treat Hypertrophic Cardiomyopathy
NCT00035386	PHASE2	COMPLETED	Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study
NCT00430833	PHASE2	UNKNOWN	CHANCE - Candesartan in Hypertrophic Cardiomyopathy
NCT00500552	PHASE2	COMPLETED	Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy
NCT01150461	PHASE2	COMPLETED	Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy
NCT01230918	PHASE2	TERMINATED	Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis
NCT01447654	PHASE2	COMPLETED	Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic Cardiomyopathy
NCT01696370	PHASE2	UNKNOWN	Trimetazidine Therapy in Hypertrophic Cardiomyopathy
NCT01912534	PHASE2	COMPLETED	Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
NCT02590809	PHASE2	COMPLETED	Hypertrophic Cardiomyopathy Symptom Release by BX1514M
NCT03496168	PHASE2	COMPLETED	Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER
NCT03532802	PHASE2	COMPLETED	The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.